Core Insights - Can-Fite BioPharma Ltd. announced that Namodenoson provided clinical stabilization for a patient with advanced decompensated liver cirrhosis, leading to a successful liver transplantation [1][2] Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule drugs for oncological and inflammatory diseases, with a pipeline that includes Namodenoson [1][6] - The company is currently evaluating Namodenoson in multiple clinical trials, including a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for Metabolic Dysfunction-associated Steatohepatitis (MASH) [5][6] Product Details - Namodenoson is an orally bioavailable A3 adenosine receptor (A3AR) agonist known for its anti-inflammatory and anti-fibrotic properties, with a favorable safety profile demonstrated in previous studies [3][5] - The drug has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for hepatocellular carcinoma by the U.S. FDA [6] Market Context - In 2017, approximately 10.6 million people globally were affected by decompensated cirrhosis, with limited treatment options available for advanced stages of the disease [4] - The global liver cirrhosis treatment market is projected to grow from around $7.6 billion in 2024 to over $15 billion by 2031, indicating a significant opportunity for new therapies [4]